August 2026 Catalyst Events
- 2026-08-02: RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) — Replimune Group Inc. — Regulatory Decision
- 2026-08-03: obrixtamig with zocilurtatug pelitecan (zoci, formerly ZL-1310) — Zai Lab Limited — Phase 1/2
- 2026-08-03: Piclidenoson — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Submission
- 2026-08-03: Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC) — AIM ImmunoTech Inc. — Topline Data
- 2026-08-03: RP-A501 — Rocket Pharmaceuticals Inc. — Initial Data
- 2026-08-03: Ebribafusp (AKB-097 (ADX-097)) — Akebia Therapeutics Inc. — Initial Data
- 2026-08-03: Olomorasib - (LOXO-RAS-20001) — Eli Lilly and Company — Phase 1/2
- 2026-08-03: Ibezapolstat — Acurx Pharmaceuticals Inc. — Submission
- 2026-08-03: Pemvidutide - (PERFORMA) — Altimmune Inc. — Topline Data
- 2026-08-03: EB103 (CD19) - (STARLIGHT-1) — Estrella Immunopharma Inc. — Phase 1/2
- 2026-08-04: mRNA-1469 — Moderna Inc. — Phase 1
- 2026-08-04: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-08-04: Bexobrutideg - (DAYBreak CLL-306) — Nurix Therapeutics Inc. — Submission
- 2026-08-04: Sigvotatug vedotin (PF-08046047) - (SigVie-002) — Pfizer Inc. — Phase 3
- 2026-08-05: Rusfertide - (REVIVE) — Protagonist Therapeutics Inc. — Regulatory Decision
- 2026-08-05: CT-95 (mesothelin) — Context Therapeutics Inc. — Topline Data
- 2026-08-05: ORZEYFUL (Oveporexton (TAK-861-2001)) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — Approved
- 2026-08-05: Bria-Pros+ — BriaCell Therapeutics Corp. — Conference Presentation
- 2026-08-05: LX2020 - (HEROIC-PKP2) — Lexeo Therapeutics, Inc. — Interim Data
- 2026-08-05: ACR-2316 — Acrivon Therapeutics Inc. — Phase 1/2
- 2026-08-05: EB-003 (EVM301 series) — Enveric Biosciences Inc. — Submission
- 2026-08-05: mRNA-1010 - (P304) — Moderna Inc. — Regulatory Decision
- 2026-08-05: mRNA-1010 - (P304) — Moderna Inc. — Regulatory Decision
- 2026-08-06: BMN 401 (INZ-701) - (ENERGY-2) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-08-06: BMN 401 (INZ-701) - (ENERGY-1) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-08-06: TUDRIQEV (vusolimogene oderparepvec-wtpg) and OPDIVO (nivolumab) - (IGNYTE-3) — Replimune Group Inc. — Approved
- 2026-08-06: LN-145 - (IOV-LUN-202) — Iovance Biotherapeutics Inc. — Submission
- 2026-08-06: OCS-01 - (DIAMOND-1) — Oculis Holding AG — Submission
- 2026-08-06: KSI-101 - (PEAK) — Kodiak Sciences Inc — Topline Data
- 2026-08-06: CMND-100 — Clearmind Medicine Inc. — Phase 1/2
- 2026-08-06: PGN-EDODM2 - (FREEDOM-DM1/2) — PepGen Inc. — End of Phase Meeting
- 2026-08-06: Bezisterim (NE3107) - (SUNRISE-PD) — BioVie Inc. — Phase 2
- 2026-08-06: Tanruprubart (ANX005) - (FORWARD) — Annexon Inc. — Submission
- 2026-08-06: Fasedienol (PH94B) - (PALISADE-2) — Vistagen Therapeutics Inc. — Topline Data
- 2026-08-06: KSI-101 - (PINNACLE) — Kodiak Sciences Inc — Topline Data
- 2026-08-06: TransCon hGH/TransCon CNP combination - (COACH) — Ascendis Pharma A/S — Conference Presentation
- 2026-08-06: SKNY-1 — MIRA Pharmaceuticals Inc. — Preclinical
- 2026-08-06: mRNA-1010 - (P304) — Moderna Inc. — Approved
- 2026-08-06: agenT-797 - (C-1300-02) — MiNK Therapeutics Inc. — End of Phase Meeting
- 2026-08-06: zabilugene almadenorepvec (VCN-01) in combination with gemcitabine/nab-paclitaxel -(VIRAGE2) — Theriva Biologics, Inc. — End of Phase Meeting
- 2026-08-06: ENFLONSIA (clesrovimab) - (MK-1654-007/SMART) — Merck & Company Inc. — Regulatory Decision
- 2026-08-07: KETAFREE — NRX Pharmaceuticals Inc. — Regulatory Decision
- 2026-08-07: Apitegromab - (SAPPHIRE) — Scholar Rock Holding Corporation — Regulatory Decision
- 2026-08-07: modzatinib (ATI-2138) — Aclaris Therapeutics Inc. — Phase 2b
- 2026-08-07: NBIP-'1968 — Neurocrine Biosciences Inc. — Initial Data
- 2026-08-08: Serabelisib and sapanisertib (FTH-PIK-201) - (PIKTOR) — Faeth Therapeutics Inc. — Conference Presentation
- 2026-08-09: BMN 333 - (ASPEN) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-08-09: BMN 401 (INZ-701) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-08-10: SPY072 - (SKYLIGHT) — Spyre Therapeutics Inc. — Topline Data
- 2026-08-10: Prolastin-C (Alpha-1 MP) - (SPARTA) — Grifols S.A. — Topline Data
- 2026-08-10: Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007) — Kura Oncology Inc. — Preclinical
- 2026-08-10: ABCL635 — AbCellera Biologics Inc. — Topline Data
- 2026-08-10: ART27.13 - (Investigator-Initiated Study) - (DREAM) — Artelo Biosciences Inc. — Interim Data
- 2026-08-10: SION-451 + Galicaftor (SION-2222) — Sionna Therapeutics Inc. — Topline Data
- 2026-08-10: SION-451 + SION-109 — Sionna Therapeutics Inc. — Topline Data
- 2026-08-10: Nanobody sonelokimab - (IZAR-1) — MoonLake Immunotherapeutics — Regulatory Decision
- 2026-08-10: Divesiran (SLN124) - (SANRECO) — Silence Therapeutics Plc — Topline Data
- 2026-08-10: TNX-103 (oral levosimendan) - (LEVEL) — Tenax Therapeutics Inc. — Conference Presentation
- 2026-08-10: SION-719 - (PreciSION CF) — Sionna Therapeutics Inc. — Topline Data
- 2026-08-10: DT120 ODT (MM120) (lysergide D-tartrate, LSD) - (Voyage) — Definium Therapeutics Inc. — Topline Data
- 2026-08-10: ABCL635 — AbCellera Biologics Inc. — Topline Data
- 2026-08-10: KETAFREE — NRX Pharmaceuticals Inc. — Conference Presentation
- 2026-08-11: Tinlarebant (LBS-008) - (DRAGON) — Belite Bio Inc — Regulatory Decision
- 2026-08-11: PDS0101 in combination with KEYTRUDA - (VERSATILE-003) — PDS Biotechnology Corporation — Phase 3
- 2026-08-11: RenovoGem - (TIGeR-PaC) — RenovoRx Inc. — Topline Data
- 2026-08-11: OV888/GV101 — Ovid Therapeutics Inc. — Phase 2
- 2026-08-11: ACI-7104.056 - (VacSYn) — AC Immune SA — Interim Data
- 2026-08-12: Zipalertinib (CLN-081/TAS6417) - (REZILIENT3) — Cullinan Therapeutics Inc. — Submission
- 2026-08-12: DT120 ODT (MM120) (lysergide D-tartrate, LSD) - (Voyage) — Definium Therapeutics Inc. — Topline Data
- 2026-08-12: NEO100-01 — NeOnc Technologies Holdings Inc. — End of Phase Meeting
- 2026-08-12: NEO100-01 — NeOnc Technologies Holdings Inc. — Topline Data
- 2026-08-13: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) — Cerenome Inc Com Par $0.0001 (New) Jan 2026 — Conference Presentation
- 2026-08-13: ST-01156 — BeyondSpring Inc. — IND-Enabling
- 2026-08-13: ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) - (EXCALIBER-RRMM) — Bristol-Myers Squibb Company — Regulatory Decision
- 2026-08-13: EP-104GI - (RESOLVE) — Eupraxia Pharmaceuticals Inc. — Interim Data
- 2026-08-13: ASC40 (denifanstat) — Sagimet Biosciences Inc. — Phase 3
- 2026-08-13: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) — Cerenome Inc Com Par $0.0001 (New) Jan 2026 — Conference Presentation
- 2026-08-13: Florquinitau (MK-6240) — Lantheus Holdings Inc. — Regulatory Decision
- 2026-08-14: FT819 - (RECLAIM-LN) — Fate Therapeutics Inc. — Phase 2
- 2026-08-14: TAUKLARIFY (Florquinitau F 18 injection (MK-6240)) — Lantheus Holdings Inc. — Approved
- 2026-08-15: ABBV-706 — AbbVie Inc. — Conference Presentation
- 2026-08-17: KETAFREE — NRX Pharmaceuticals Inc. — Regulatory Decision
- 2026-08-17: Serabelisib and sapanisertib (FTH-PIK-201) - (PIKTOR) — Faeth Therapeutics Inc. — Topline Data
- 2026-08-17: Rexlemestrocel-L - (MSB-DR004) — Mesoblast Limited — Phase 3
- 2026-08-17: Efgartigimod - (ALKIVIA) — argenx SE — Conference Presentation
- 2026-08-17: ESK-001 - (ONWARD3) — Alumis Inc. — End of Phase Meeting
- 2026-08-17: Aramchol and Xtandi (enzalutamide) — Galmed Pharmaceuticals Ltd. — Preclinical
- 2026-08-17: ENHERTU (trastuzumab deruxtecan) - (DESTINY-Lung04) — Daiichi Sankyo Co., Ltd. ADR — Conference Presentation
- 2026-08-17: Volrustomig (MEDI5752) - (eVOLVE-Lung02) — AstraZeneca PLC — Phase 3
- 2026-08-17: UGN-103 - (UTOPIA) — UroGen Pharma Ltd. — Submission
- 2026-08-17: ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) — HUTCHMED (China) Limited — End of Phase Meeting
- 2026-08-17: DURAVYU (EYP-1901) - (LUGANO) — EyePoint Inc. — Submission
- 2026-08-17: Namodenoson - (CF102-222PC) — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Conference Presentation
- 2026-08-17: Tyvaso (treprostinil) - (TETON PPF) — United Therapeutics Corporation — Topline Data
- 2026-08-17: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) — Cerenome Inc Com Par $0.0001 (New) Jan 2026 — End of Phase Meeting
- 2026-08-17: EVX-03 — Evaxion A/S — Initial Data
- 2026-08-17: iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone - (EXCALIBER RRMM) — Bristol-Myers Squibb Company — Regulatory Decision
- 2026-08-17: KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) — Pfizer Inc. — Regulatory Decision
- 2026-08-18: NV-387 (gummies) — NanoViricides Inc. — Phase 2
- 2026-08-18: Pelareorep in combination with bevacizumab (Avastin) and leucovorin, fluorouracil, irinotecan (FOLFIRI) - (REO 033) — Oncolytics Biotech Inc. — End of Phase Meeting
- 2026-08-18: AKTX-101 — Akari Therapeutics Plc — Initial Data
- 2026-08-18: Avexitide (Exendin 9-39) - (LUCIDITY) — Amylyx Pharmaceuticals Inc. — End of Phase Meeting
- 2026-08-18: EYC-0305 - (OVERTURE) — Ascendis Pharma A/S — Phase 1/2
- 2026-08-18: PLN-101095 - (FORTIFY) — Pliant Therapeutics Inc. — Submission
- 2026-08-19: TTI-109 — Tvardi Therapeutics Inc. — Submission
- 2026-08-19: Garetosmab - (OPTIMA) — Regeneron Pharmaceuticals Inc. — Submission
- 2026-08-19: GENGLYCOS (pariglasgene brecaparvovec-opnr) — Ultragenyx Pharmaceutical Inc. — Approved
- 2026-08-19: intismeran autogene (intismeran; V940 or mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-001) — Merck & Company Inc. — Submission
- 2026-08-19: ATEV - (V007) — Humacyte Inc. — End of Phase Meeting
- 2026-08-19: Ecopipam (EBS-101) - (D1AMOND) — Teva Pharmaceutical Industries Limited American Depositary Shares — Regulatory Decision
- 2026-08-19: ABP-450 (prabotulinumtoxinA) - (BOTOX biosimilar) — AEON Biopharma Inc. Class A — End of Phase Meeting
- 2026-08-19: eRapa (rapamycin, sirolimus) - (Serenta) — Biodexa Pharmaceuticals plc — Conference Presentation
- 2026-08-19: TTI-109 — Tvardi Therapeutics Inc. — Conference Presentation
- 2026-08-20: NASARIX (PL-14) — Polyrizon Ltd. — Preclinical
- 2026-08-20: RAD202 (177Lu-RAD202) - (HEAT) — Radiopharm Theranostics Limited — Phase 1
- 2026-08-21: Etripamil (AFib-RVR) - (ReVeRA-301) — Milestone Pharmaceuticals Inc. — Phase 3
- 2026-08-22: Deramiocel (CAP-1002) - (HOPE-3) — Capricor Therapeutics Inc. — Regulatory Decision
- 2026-08-22: Deramiocel (CAP-1002) - (HOPE-3) — Capricor Therapeutics Inc. — Regulatory Decision
- 2026-08-22: Deramiocel (CAP-1002) - (HOPE-2) — Capricor Therapeutics Inc. — Regulatory Decision
- 2026-08-23: DTX401 AAV gene therapy (pariglasgene brecaparvovec) — Ultragenyx Pharmaceutical Inc. — Regulatory Decision
- 2026-08-24: Gamgertamig (OM336) — Lakefront Biotherapeutics — Phase 1b
- 2026-08-24: IMAAVY (nipocalimab-aahu) - (ENERGY) — Johnson & Johnson — Conference Presentation
- 2026-08-24: ALKS 2680 - (Vibrance-1) — Alkermes plc — Phase 2
- 2026-08-24: PBGENE-DMD - (FUNCTION-DMD) — Precision BioSciences Inc. — Initial Data
- 2026-08-24: ERAS-0015 — Erasca Inc. — Phase 1
- 2026-08-24: Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211) — Biomea Fusion Inc. — Topline Data
- 2026-08-24: Privosegtor - (PIONEER-1) — Oculis Holding AG — Submission
- 2026-08-24: clemidsogene lanparvovec (RGX-121) - (CAMPSIITE) — REGENXBIO Inc. — Submission
- 2026-08-24: Deramiocel (CAP-1002) - (HOPE-3) — Capricor Therapeutics Inc. — Regulatory Decision
- 2026-08-24: LEQEMBI IQLIK (lecanemab-irmb)(at-home injection) — Biogen Inc. — Regulatory Decision
- 2026-08-25: SPY072 - (SKYWAY-RD, basket study) — Spyre Therapeutics Inc. — Topline Data
- 2026-08-25: Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) — Zymeworks Inc. — Conference Presentation
- 2026-08-25: RenovoGem - (TIGeR-PaC) — RenovoRx Inc. — Topline Data
- 2026-08-25: Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) — Zymeworks Inc. — Regulatory Decision
- 2026-08-25: Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) — Jazz Pharmaceuticals plc — Regulatory Decision
- 2026-08-26: Neoadjuvant botensilimab plus balstilimab - (NEST) — Agenus Inc. — Phase 2
- 2026-08-26: Ivonescimab - (HARMONi-GI3) — Summit Therapeutics Inc. — Regulatory Decision
- 2026-08-26: RV 01 (Betabart) — Radiopharm Theranostics Limited — Initial Data
- 2026-08-26: DATROWAY (datopotamab deruxtecan) plus rilvegostomig - (TROPION-Urothelial04) — AstraZeneca PLC — Phase 3
- 2026-08-26: Gedatolisib with Fulvestrant - (VIKTORIA-2) — Celcuity Inc. — Submission
- 2026-08-26: RASONQUE (Daraxonrasib) - (RASolute 302) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-08-27: ADI-212 — Adicet Bio Inc. — IND-Enabling
- 2026-08-27: COMIRNATY LP.8.1 — Pfizer Inc. — Approved
- 2026-08-27: Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) - (ARTISTRY-2) — Gilead Sciences Inc. — Approved
- 2026-08-27: Atebimetinib + GnP - (MAPKeeper 301) — Immuneering Corporation — Topline Data
- 2026-08-27: Tezspire (tezepelumab) - (CROSSING) — AstraZeneca PLC — Conference Presentation
- 2026-08-27: Paxalisib — Kazia Therapeutics Limited — Interim Data
- 2026-08-27: Spikevax and mNEXSPIKE - (LP.8.1 variant) — Moderna Inc. — Approved
- 2026-08-27: Brepocitinib - (VALOR) — Roivant Sciences Ltd. — Approved
- 2026-08-27: YCANTH (cantharidin, VP-102) - (COVE-3) — Verrica Pharmaceuticals Inc. — Topline Data
- 2026-08-27: ECUR-506 - (OTC-HOPE) — Precision BioSciences Inc. — Conference Presentation
- 2026-08-27: Canvuparatide (MBX 2109) - (oPTimize) — MBX Biosciences Inc. — Phase 3
- 2026-08-27: Varsetatug masetecan (EpCAM PROBODY Topo-1 ADC, CX-2051) - (Varseta-M) — CytomX Therapeutics Inc. — Phase 1
- 2026-08-27: ECUR-506 - (OTC-HOPE) — Precision BioSciences Inc. — Conference Presentation
- 2026-08-27: Bictegravir and Lenacapavir - (ARTISTRY-2) — Gilead Sciences Inc. — Regulatory Decision
- 2026-08-28: ION775 — Ionis Pharmaceuticals Inc. — Phase 1
- 2026-08-28: CTX310 — CRISPR Therapeutics AG — Phase 1
- 2026-08-28: VASCEPA (icosapent ethyl) - (REDUCE-IT) — Amarin Corporation plc — Conference Presentation
- 2026-08-28: MIMRYLO (Rusfertide) - (VERIFY) — Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) — End of Phase Meeting
- 2026-08-28: Mounjaro (tirzepatide) — Eli Lilly and Company — Submission
- 2026-08-28: Aficamten - (ACACIA-HCM) — Cytokinetics Incorporated — Phase 3
- 2026-08-28: QRX003 - (CL-QRX003-004) — Quoin Pharmaceuticals Ltd. — Submission
- 2026-08-28: TransCon CNP (navepegritide) - (ApproaCH) — Ascendis Pharma A/S — Conference Presentation
- 2026-08-28: VASCEPA (icosapent ethyl) - (REDUCE-IT) — Amarin Corporation plc — Conference Presentation
- 2026-08-28: ION775 — Ionis Pharmaceuticals Inc. — Conference Presentation
- 2026-08-29: Aficamten (CK-274) - (MAPLE-HCM) — Cytokinetics Incorporated — Phase 3
- 2026-08-29: Aficamten - (ACACIA-HCM) — Cytokinetics Incorporated — Conference Presentation
- 2026-08-29: TNX-103 (oral levosimendan) - (LEVEL) — Tenax Therapeutics Inc. — Topline Data
- 2026-08-30: Zilebesiran - (KARDIA-3) — Alnylam Pharmaceuticals Inc. — Phase 3
- 2026-08-30: Plozasiran (ARO-APOC3-3004) - (SHASTA-4) — Arrowhead Pharmaceuticals Inc. — Phase 3
- 2026-08-30: Plozasiran (ARO-APOC3-3003) - (SHASTA-3) — Arrowhead Pharmaceuticals Inc. — Phase 3
- 2026-08-30: Vutrisiran - (HELIOS-B) — Alnylam Pharmaceuticals Inc. — Phase 3
- 2026-08-30: TNX-103 (oral levosimendan) - (LEVEL) — Tenax Therapeutics Inc. — Phase 3
- 2026-08-30: Vutrisiran - (HELIOS-B) — Alnylam Pharmaceuticals Inc. — Conference Presentation
- 2026-08-30: Plozasiran (ARO-APOC3-3004) - (SHASTA-4) — Arrowhead Pharmaceuticals Inc. — Full Results
- 2026-08-30: Zilebesiran - (KARDIA-3) — Roche Holding AG ADR — Conference Presentation
- 2026-08-30: Plozasiran (ARO-APOC3-3003) - (SHASTA-3) — Arrowhead Pharmaceuticals Inc. — Conference Presentation
- 2026-08-30: KERENDIA (finerenone) - (FIND-CKD) — Bayer AG ADR — Conference Presentation
- 2026-08-30: Plozasiran (ARO-APOC3-3003) - (SHASTA-3) — Arrowhead Pharmaceuticals Inc. — Conference Presentation
- 2026-08-30: Plozasiran (ARO-APOC3-3004) - (SHASTA-4) — Arrowhead Pharmaceuticals Inc. — Full Results
- 2026-08-31: MER769 — Eli Lilly and Company — Initial Data
- 2026-08-31: ORPATHYS (savolitinib) and TAGRISSO (osimertinib) - (SANOVO) — HUTCHMED (China) Limited — Conference Presentation
- 2026-08-31: Selinexor (XPORT-MF-034) - (SENTRY) — Karyopharm Therapeutics Inc. — Submission
- 2026-08-31: MER511 - (NEXUS) — Eli Lilly and Company — Initial Data
- 2026-08-31: AVT80 (biosimilar to Entyvio) - (AVT80-GL-P01) — Alvotech — BsUFA
- 2026-08-31: evuzamitide (I 124 evuzamitide) - (REVEAL) — Bayer AG ADR — Submission
- 2026-08-31: Taltz (ixekizumab) and Zepbound (tirzepatide) - (TOGETHER-PsO) — Eli Lilly and Company — Conference Presentation
- 2026-08-31: QTORIN rapamycin - (SELVA) — Palvella Therapeutics Inc. — Submission
- 2026-08-31: TTX-MC138 - (PRE-I-SPY) — TransCode Therapeutics Inc. — Submission
- 2026-08-31: EDG-7500 - (CIRRUS-HCM) — Edgewise Therapeutics Inc. — Phase 2
- 2026-08-31: Taltz (ixekizumab) and Zepbound (tirzepatide) - (TOGETHER-PsA) — Eli Lilly and Company — Conference Presentation
- 2026-08-31: Dextromethorphan-bupropion (AXS-05) - (SUMMIT) — Axsome Therapeutics Inc. — Phase 3
- 2026-08-31: Bezisterim (NE3107) - (ADDRESS-LC) — BioVie Inc. — Topline Data
- 2026-08-31: Rezatapopt (PC14586) - (PYNNACLE) — PMV Pharmaceuticals Inc. — End of Phase Meeting
- 2026-08-31: Mavacamten - (MAVA-LTE) — Bristol-Myers Squibb Company — Phase 3
- 2026-08-31: EDG-7500 - (CIRRUS-HCM) — Edgewise Therapeutics Inc. — Conference Presentation
- 2026-08-31: STRO-004 - (STRIVE-01) — Sutro Biopharma Inc. — Initial Data
- 2026-08-31: Efzofitimod - (EFZO-FIT) — aTyr Pharma Inc. — End of Phase Meeting
- 2026-08-31: Aficamten - (ACACIA-HCM) — Cytokinetics Incorporated — Conference Presentation
- 2026-08-31: ABCL635 — AbCellera Biologics Inc. — Topline Data
- 2026-08-31: Rusfertide - (REVIVE) — Protagonist Therapeutics Inc. — Regulatory Decision
- 2026-08-31: DURAVYU (EYP-1901) - (LUGANO) — EyePoint Inc. — Topline Data
- 2026-08-31: Selinexor (XPORT-MF-034) - (SENTRY) — Karyopharm Therapeutics Inc. — Submission
- 2026-08-31: Wainua (eplontersen) - (CARDIO-TTRansform) — Ionis Pharmaceuticals Inc. — Conference Presentation
- 2026-08-31: ION775 — Ionis Pharmaceuticals Inc. — Conference Presentation
- 2026-08-31: Pelareorep in combination with bevacizumab (Avastin) and leucovorin, fluorouracil, irinotecan (FOLFIRI) - (REO 033) — Oncolytics Biotech Inc. — End of Phase Meeting
- 2026-08-31: Wainua (eplontersen) - (CARDIO-TTRansform) — Ionis Pharmaceuticals Inc. — Conference Presentation
- 2026-08-31: Prulacabtagene leucel (prula-cel, formerly ADI-001) — Adicet Bio Inc. — Interim Data
- 2026-08-31: ML-007C-MA - (ZEPHYR) — MapLight Therapeutics Inc. — Topline Data
- 2026-08-31: Remlifanserin (ACP-204) - (RADIANT) — ACADIA Pharmaceuticals Inc. — Topline Data
- 2026-08-31: DURAVYU (EYP-1901) - (LUGANO) — EyePoint Inc. — Topline Data
- 2026-08-31: S4V2 Shigella Vaccine - (CHIM study) — Valneva SE — Submission
- 2026-08-31: Laromestrocel (lomecel-B) - (ELPIS II) — Longeveron Inc. — Topline Data
- 2026-08-31: Nanobody (sonelokimab) - (VELA-TEEN) — MoonLake Immunotherapeutics — Interim Data
- 2026-08-31: DURAVYU (EYP-1901) - (LUCIA) — EyePoint Inc. — Topline Data
- 2026-08-31: SVR12 in combination of bemnifosbuvir and ruzasvir - (C-BEYOND) — Atea Pharmaceuticals Inc. — Topline Data
- 2026-08-31: Furmonertinib - (FURVENT) — ArriVent BioPharma Inc. — Topline Data
- 2026-08-31: Nanobody sonelokimab - (IZAR-1) — MoonLake Immunotherapeutics — Initial Data
- 2026-08-31: Zanzalintinib - (STELLAR-304) — Exelixis Inc. — Topline Data
- 2026-08-31: EscharEx - (VALUE) — MediWound Ltd. — Interim Data
- 2026-08-31: ALXN1840 (WTX101) - (FoCus) — AstraZeneca PLC — Submission
- 2026-08-31: Garetosmab - (OPTIMA) — Regeneron Pharmaceuticals Inc. — Regulatory Decision
- 2026-08-31: MICVO (maMICVO) — Pyxis Oncology Inc. — End of Phase Meeting
- 2026-08-31: Bempikibart - (SIGNAL-AA) — Q32 Bio Inc. — Topline Data
- 2026-08-31: MGC026 — MacroGenics Inc. — Initial Data
- 2026-08-31: NMRA-898 — Neumora Therapeutics Inc. — End of Phase Meeting
- 2026-08-31: RAD202 (177Lu-RAD202) - (HEAT) — Radiopharm Theranostics Limited — Interim Data
- 2026-08-31: 177Lu-RAD204 — Radiopharm Theranostics Limited — Interim Data
- 2026-08-31: CLYM116 — Climb Bio Inc. — Initial Data
- 2026-08-31: NMRA-861 — Neumora Therapeutics Inc. — End of Phase Meeting
- 2026-08-31: SION-451 + SION-109 — Sionna Therapeutics Inc. — Topline Data
- 2026-08-31: SION-451 + Galicaftor (SION-2222) — Sionna Therapeutics Inc. — Topline Data
- 2026-08-31: STRO-004 — Sutro Biopharma Inc. — Initial Data
- 2026-08-31: Empasiprubart - (VARVARA) — argenx SE — Topline Data
- 2026-08-31: CT-95 (mesothelin) — Context Therapeutics Inc. — Initial Data
- 2026-08-31: micvotabart pelidotin (PYX-201-101) - (MICVO) — Pyxis Oncology Inc. — Interim Data
- 2026-08-31: Emiltatug Ledadotin (XMT-1660) - (Emi-Le) — Day One Biopharmaceuticals Inc. — Initial Data
- 2026-08-31: CLR 125 — Cellectar Biosciences Inc. — Interim Data
- 2026-08-31: CRB-913 - (CANYON-1) — Corbus Pharmaceuticals Holdings Inc. — Topline Data
- 2026-08-31: NEO100 — NeOnc Technologies Holdings Inc. — Initial Data
- 2026-08-31: NGN-401 - (Embolden) — Neurogene Inc. — Interim Data
- 2026-08-31: RM-718 — Rhythm Pharmaceuticals Inc. — Interim Data
- 2026-08-31: Resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) - (RESET-MG) — Cabaletta Bio Inc. — Interim Data
- 2026-08-31: ENTR-601-45 - (ELEVATE-45-201) — Entrada Therapeutics Inc. — Initial Data
- 2026-08-31: Belzupacap sarotalocan (AU-011) — Aura Biosciences Inc. — Initial Data
- 2026-08-31: SION-719 - (PreciSION CF) — Sionna Therapeutics Inc. — Interim Data
- 2026-08-31: NEO100-01 — NeOnc Technologies Holdings Inc. — Topline Data
- 2026-08-31: Lorigerlimab - (LINNET) — MacroGenics Inc. — Interim Data
- 2026-08-31: Obexelimab - (SunStone) — Zenas BioPharma Inc. — Topline Data
- 2026-08-31: TYRA-300 - (SURF302) — Tyra Biosciences Inc. — Initial Data
- 2026-08-31: Casdozokitug/toripalimab/bevacizumab — Coherus Oncology Inc. — Initial Data
- 2026-08-31: Divesiran (SLN124) - (SANRECO) — Silence Therapeutics Plc — Topline Data
FDA Events Calendar
August 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
1
3
6
10
11
12
13
15
16
18
25
30
Clinical Read
Regulatory
Meetings & Presentations